Capital Access Window
Ondine Biomedical Inc. has announced its intention to utilize AIM's new Capital Access Window for a proposed equity capital raise, which will also include a retail offer. The funds raised will support the publication of full LANTERN trial analyses, advance FDA engagement for an NDA submission in mid-2027, progress commercial pilots, and invest in sales and marketing to expand product deployments and adoption. The company also plans to strengthen its board and senior management team. Trading of the company's shares on AIM will be temporarily paused until further announcements regarding the fundraise results are made.
Select text to share a quote on X · sign in to keep highlights & notes in your OBI notes
Ondine Biomedical Inc. (AIM: OBI), a leader in light-activated antimicrobial therapies for the prevention and treatment of hospital infections, announces its intention to utilise AIM’s new Capital Access Window in connection with a proposed equity capital raise (the “Proposed Fundraise”). The Company also intends to launch a retail offer to enable retail investors to participate on the same terms.
Proposed Fundraise
The Company is undertaking the Proposed Fundraise to provide funding towards publishing the full LANTERN trial analyses, advancing FDA engagement with the intention of submitting the NDA in mid-2027, as well as progressing commercial pilots and investing further in sales and marketing to broaden product deployments and deepen adoption in markets where Steriwave is already authorised, whilst also having access to additional working capital to fund growth. Finally, the Company plans to continue to enhance and strengthen the capabilities of the Board and its senior management team as the Company’s focus shifts to the critical next stage of its growth journey.
Further details of the Proposed Fundraise will be announced in due course.
Capital Access Window
Following the updates to the AIM Rules for Companies announced in August 2026, the Company will enter a Capital Access Window with effect from 7.30 a.m. BST today. This is a voluntary temporary pause in the trading of the Company’s common shares on AIM, intended to make it easier to reach a broader range of investors and provide pricing stability during a fundraise. The Capital Access Window will remain in place until a further announcement is made detailing the results of the Proposed Fundraise.
About Ondine Biomedical Inc.
Regulatory approvals, clearances and authorisations vary by jurisdiction, and indications, claims and availability may differ between markets. No statement in this announcement should be interpreted as representing approval, clearance, authorisation or availability in any jurisdiction, or for any use, where such status has not been granted.
U.S. Regulatory Status
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.